Semaglutide is a long-acting human GLP-1 analogue that shares 94% structural homology with native GLP-1
Tirzepatide dosing for compounded vials Compounded tirzepatide typically comes in 10 mg/mL or 20 mg/mL concentrations, though some pharmacies offer different formulations
If GI symptoms are manageable, continue at this dose for the full four weeks before considering the next increase
[15] [37] [38] In August 2025, the Food and Drug Administration (FDA) expanded the indication for semaglutide (as Wegovy) to include the treatment of noncirrhotic metabolic-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults
Instead, the transition typically begins at the starting tirzepatide dose of 2.5 mg weekly, regardless of the patients previous semaglutide level
This produces a sensation of fullness and generally means you eat less
